Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors

Simple item page
dc.contributor.authorTymms, Kathleen
dc.contributor.authorLittlejohn, Geoffrey
dc.contributor.authorGriffiths, Hedley
dc.contributor.authorde Jager, Julien
dc.contributor.authorBIRD, Paul
dc.contributor.authorJoshua, Fred
dc.contributor.authorNash, Peter
dc.contributor.authorHandel, Malcolm
dc.contributor.authorMcManus, Hamish
dc.contributor.authorButcher, Belinda E
dc.contributor.authorYoussef, Peter
dc.date.accessioned2021-12-17T03:27:38Z
dc.date.issued2018
dc.date.updated2020-11-23T12:00:19Z
dc.description.abstractThe aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease. Treatment persistence was calculated. Data from 3749 patients were extracted (adalimumab n = 1518; certolizumab n = 298; etanercept n = 1068; golimumab n = 865). The mean (SD) ages of patients were 51.7 (14.2) years for adalimumab, 53.7 (14.0) years for certolizumab, 52.8 (14.3) years for etanercept and 52.3 (14.6) years for golimumab, with disease durations 7.7 (10.5), 8.8 (9.2), 8.1 (10.4) and 7.3 (9.7) years, respectively. Two thirds of the patients were women. There was no significant difference in treatment persistence by treatment in the overall population (adalimumab 33.6 [95% CI 28.6–40.7], certolizumab 24.8 [95% CI 21.3–42.1], etanercept 27.6 [95% CI 23.4–36.5], golimumab 30.3 [95% CI 23.26–36.5]; months, p = 0.545), or in the propensity score-matched population. No safety signals were detected. In this real-world biologic-naïve Australian inflammatory rheumatic disease cohort treated with subcutaneous TNF inhibitors during the period 2010–2016, there was no difference in treatment persistence between agents.en_AU
dc.description.sponsorshipThis study was sponsored by Janssen-Cilag Pty Ltd., Australia, the manufacturer of golimumab (SIMPONI).en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0770-3198en_AU
dc.identifier.urihttp://hdl.handle.net/1885/256653
dc.language.isoen_AUen_AU
dc.publisherSpringeren_AU
dc.rights© International League of Associations for Rheumatology (ILAR) 2018en_AU
dc.sourceClinical Rheumatologyen_AU
dc.subjectAnkylosing spondylitisen_AU
dc.subjectMedication persistenceen_AU
dc.subjectPsoriatic arthritisen_AU
dc.subjectRheumatoid arthritisen_AU
dc.subjectSpondyloarthritisen_AU
dc.subjectTumour necrosis factor inhibitorsen_AU
dc.subjectUndifferentiated arthritisen_AU
dc.titleTreatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue6en_AU
local.bibliographicCitation.lastpage1623en_AU
local.bibliographicCitation.startpage1617en_AU
local.contributor.affiliationTymms, Kathleen, College of Health and Medicine, ANUen_AU
local.contributor.affiliationLittlejohn, Geoffrey, Monash Universityen_AU
local.contributor.affiliationGriffiths, Hedley, Barwon Rheumatology Serviceen_AU
local.contributor.affiliationde Jager, Julien, Gold Coast Rheumatologyen_AU
local.contributor.affiliationBIRD, Paul, Combined Rheumatology Practiceen_AU
local.contributor.affiliationJoshua, Fred, Combined Rheumatologyen_AU
local.contributor.affiliationNash, Peter, University of Queenslanden_AU
local.contributor.affiliationHandel, Malcolm, Janssen-Cilag Australia Pty Ltden_AU
local.contributor.affiliationMcManus, Hamish, Prospectionen_AU
local.contributor.affiliationButcher, Belinda E, WriteSource Medical Pty Ltden_AU
local.contributor.affiliationYoussef, Peter, Royal Prince Alfred Hospitalen_AU
local.contributor.authoremailrepository.admin@anu.edu.auen_AU
local.contributor.authoruidTymms, Kathleen, u5095765en_AU
local.description.embargo2099-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor110799 - Immunology not elsewhere classifieden_AU
local.identifier.absseo920199 - Clinical Health (Organs, Diseases and Abnormal Conditions) not elsewhere classifieden_AU
local.identifier.ariespublicationu5234101xPUB81en_AU
local.identifier.citationvolume37en_AU
local.identifier.doi10.1007/s10067-018-4105-3en_AU
local.identifier.uidSubmittedByu5234101en_AU
local.publisher.urlhttp://link.springer.com/journal/10067en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
01_Tymms_Treatment_patterns_among_2018.pdf
Size:
537.29 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2024 LYRASIS